On Wednesday, Following Stocks were among the “Top 50 Losers” of U.S. Stock Market: Mattson Technology, Inc (NASDAQ:MTSN), FXCM Inc (NYSE:FXCM), MasTec, Inc (NYSE:MTZ), Neuralstem, Inc (NYSEMKT:CUR)
Mattson Technology, Inc (NASDAQ:MTSN), with shares declined -11.35%, closed at $4.14.
FXCM Inc (NYSE:FXCM), with shares dropped -9.80%, settled at $2.21.
MasTec, Inc (NYSE:MTZ), with shares dipped -9.54%, and closed at $17.82, hitting new 52-week low of $16.00.
Neuralstem, Inc (NYSEMKT:CUR), plummeted -9.13%, and closed at $2.19.
Latest NEWS regarding these Stocks are depicted underneath:
Mattson Technology Inc. (NASDAQ:MTSN)
Due to analysts’ concerns of slowing DRAM demand, Mattson Technology Inc. (MTSN), fell on Wednesday. In a research note JPMorgan (JPM) analyst Harlan Sur said that Samsung (SSNLF), the largest DRAM supplier in the world, recently postponed a “meaningful level” of equipment orders and deliveries for its Line-17 DRAM by about 1 to 2 quarters. Samsung is actually slowing down its efforts to ramp DRAM capacity.
In February, Mattson Technology (MTSN) saw a noteworthy growth in short interest. As of February 27th, there was short interest totaling 1,157,448 shares, a growth of 60.4% from the February 13th total of 721,599 shares, Analyst Ratings.Net reports. Based on an average daily volume of 1,929,622 shares, the short-interest ratio is presently 0.6 days. Presently, 1.6% of the corporation’s stock are sold short.
Mattson Technology, Inc. designs, manufactures, markets, and supports semiconductor wafer processing equipment used in the fabrication of integrated circuits worldwide. The corporation offers dry strip, rapid thermal processing, and etch equipment to the semiconductor industry. Its dry strip products comprise the SUPREMA strip system that incorporates its Faraday Shielded inductively coupled plasma (ICP) radio frequency source and platform used in the production at 28 nm and 20nm technology nodes.
FXCM Inc. (NYSE:FXCM)
On last Wednesday, FXCM Inc. (FXCM), revealed detailed information regarding its systems and the broader FX market during the January 15th EUR/CHF Flash Crash. FXCM has compiled data points which demonstrate the unprecedented and extreme dysfunction of the FX market on January 15th.
On the very next day, a leading online provider of foreign exchange, or FX, trading and related services, declared for the quarter ended December 31, 2014, U.S. GAAP proceeds of $134.7 million, contrast to $113.3 million for the quarter ended December 31, 2013, an raise of 19%. U.S. GAAP net revenue attributable to FXCM Inc. was $15.8 million for the fourth quarter 2014 or $0.35 per fully diluted share, contrast to U.S. GAAP net revenue of $3.0 million or $0.08 per fully diluted share for the fourth quarter 2013.
For the twelve months ended December 31, 2014, U.S. GAAP proceeds were $463.8 million, contrast to $489.6 million for the twelve months ended December 31, 2013, a decrease of 5%. U.S. GAAP net revenue attributable to FXCM Inc. was $17.2 million for the twelve months ended December 31, 2014 or $0.39 per fully diluted share, contrast to U.S. GAAP net revenue of $14.8 million or $0.44 per fully diluted share for the twelve months ended December 31, 2013, an raise of 16% and decrease of 11% respectively.
Adjusted EBITDA for the fourth quarter 2014 was $40.8 million, contrast to $26.8 million for the fourth quarter 2013, an raise of 53%. Net revenue on an adjusted basis was $16.1 million or $0.20 per fully diluted, fully exchanged share for the fourth quarter 2014, contrast to Net revenue on an adjusted basis of $7.3 million or $0.10 per fully diluted, fully exchanged share for the fourth quarter 2013, an raise of 120% and 100% respectively.
Adjusted EBITDA for the twelve months ended December 31, 2014 was $107.3 million, contrast to $158.0 million for the twelve months ended December 31, 2013, a decrease of 32%. Net revenue on an adjusted basis was $28.2 million or $0.35 per fully diluted, fully exchanged share for the twelve months ended December 31, 2014, contrast to $57.8 million or $0.76 per fully diluted, fully exchanged share for the twelve months ended December 31, 2013, a decrease of 51% and 54% respectively.
FXCM Inc., through its auxiliaries, provides online foreign exchange (FX) trading and related services to retail and institutional customers worldwide. The corporation operates in two segments, Retail Trading and Institutional Trading. It acts as an agent between retail customers and a collection of global banks and financial institutions by making foreign currency markets for customers trading in foreign exchange spot markets.
MasTec, Inc. (NYSE:MTZ)
On Tuesday, MasTec, Inc. (MTZ), declared an update regarding its filing of its Annual Report on Form 10-K for the fiscal year ended December 31, 2014. The Audit Committee and its independent counsel are still conducting the formerly revealed independent internal investigation. As a result, the Corporation will not be able to timely file its Annual Report on Form 10-K for the fiscal year ended December 31, 2014 by today’s extended deadline following Securities and Exchange Commission rules.
The Audit Committee has not reached any conclusions and is undertaking additional review of accounting estimates. The Corporation cannot predict the outcome of the Audit Committee’s investigation, its ultimate scope or when it will be accomplished.
MasTec, Inc., an infrastructure construction corporation, provides engineering, building, installation, maintenance, and upgrade services for energy, utility, and communications infrastructure primarily in the United States.
Neuralstem, Inc. (NYSEMKT:CUR)
Neuralstem, Inc. (CUR), stated its financial results for the fourth quarter and year ended December 31, 2014.
“Neuralstem has progressed into a clinical development stage corporation focused on the central nervous system (CNS),” said Richard Garr, Neuralstem President and CEO. “During 2014 we added two established industry leaders as Independent Directors, Catherine Angell Sohn, Pharm.D. and Sandford Drexel Smith. Dr. Sohn is the former Senior Vice President of Business Development and Planned Alliance, GSK Consumer Healthcare, at GlaxoSmithKline. Mr. Smith is the former Executive Vice President of Genzyme Corporation. The Corporation moved forward two lead clinical assets: our small molecule neurogenic drug candidate NSI-189 and our spinal derived neural stem cell therapeutic candidate NSI-566. We established and/or grew clinical research programs with leading investigators at Emory University, University of California, San Diego (UCSD), University of Michigan and Massachusetts General Hospital. Our investigators published and presented proof of principle data in both lead assets as highlighted below. In 2015, we plan to start clinical development of our NSI-189 small molecule drug in a second indication for the treatment of cognitive deficit from schizophrenia, and we plan to initiate a Phase II clinical trial for the ongoing development program for the treatment of major depressive disorder (MDD). The cell therapy programs in amyotrophic lateral sclerosis (ALS), chronic spinal cord injury (cSCI) and stroke will also move forward. We expect this to be another important year ongoing our development and progress across both platforms.”
Neuralstem, Inc., a biopharmaceutical corporation, focuses on the development and commercialization of treatments for central nervous system disease based on human neural stem cells and the use of small molecule compounds. The corporation’s stem cell technology enables the isolation and expansion of human neural stem cells from various areas of the developing human brain and spinal cord enabling the generation of physiologically relevant human neurons of various types. Its clinical program products comprise NSI566, which is in Phase II clinical trials for the treatment of amyotrophic lateral sclerosis, and Phase I clinical trials for chronic spinal cord injury.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
